These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33577421)

  • 41. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
    Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Heo JY; Choi WS; Lee J; Kim WJ
    Clin Vaccine Immunol; 2012 May; 19(5):638-41. PubMed ID: 22379067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
    Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
    Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
    Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
    Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective efficacy of an inactivated chimeric H7/H5 avian influenza vaccine against highly pathogenic avian influenza H7N9 and clade 2.3.4.4 H5 viruses.
    Peng C; Hou G; Li J; Wang S; Wang Y; Cheng S; Yu X; Jin J; Jiang W
    Vet Microbiol; 2018 Sep; 223():21-26. PubMed ID: 30173747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice.
    Xu L; Bao L; Lau SY; Wu WL; Yuan J; Gu S; Li F; Lv Q; Xu Y; Pushko P; Chen H; Qin C
    Vaccine; 2016 May; 34(23):2627-33. PubMed ID: 27083426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.
    Cheong HJ; Song JY; Heo JY; Noh JY; Choi WS; Park DW; Wie SH; Kim WJ
    Clin Vaccine Immunol; 2011 Aug; 18(8):1358-64. PubMed ID: 21715575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB; Choi WS; Lee J; Song JY; Cheong HJ; Kim WJ
    Clin Vaccine Immunol; 2014 Jul; 21(7):989-96. PubMed ID: 24828092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine.
    Duan Y; Gu H; Chen R; Zhao Z; Zhang L; Xing L; Lai C; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
    PLoS One; 2014; 9(6):e99322. PubMed ID: 24937303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin.
    Song L; Xiong D; Kang X; Yang Y; Wang J; Guo Y; Xu H; Chen S; Peng D; Pan Z; Jiao X
    BMC Biotechnol; 2015 Aug; 15():79. PubMed ID: 26286143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.
    Mallett CP; Beaulieu E; Joly MH; Baras B; Lu X; Liu F; Levine MZ; Katz JM; Innis BL; Giannini SL
    Vaccine; 2015 Jul; 33(32):3784-7. PubMed ID: 26100923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.
    Chen TH; Liu YY; Jan JT; Huang MH; Spearman M; Butler M; Wu SC
    Antiviral Res; 2017 Oct; 146():213-220. PubMed ID: 28947234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.